ExploreWatchlistsPricing
  1. JP-listed companies
  2. Nxera Pharma Co., Ltd.
  3. Financials
  4. Accounts receivable, net

Nxera Pharma Co., Ltd. (4565)

Market cap
¥94.6B
P/E ratio
Nexera Pharma discovers, develops and commercializes innovative specialty pharmaceuticals to improve patient quality of life in Japan and worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndAccounts receivable, net (Million JPY)YoY (%)
Dec 31, 20257,730+15.46%
Dec 31, 20246,695+32.21%
Dec 31, 20235,064+105.69%
Dec 31, 20222,462+15.15%
Dec 31, 20212,138+127.69%
Dec 31, 2020939-51.20%
Dec 31, 20191,924+94.93%
Dec 31, 2018987

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat